Isorhapontigenin, a potential anti-AD natural product targeting multiple pathways, discovered via network proximity and gene enrichment analyses
Phytomedicine Plus · 2025-08 · 5 (3) · 100853
DOI: 10.1016/j.phyplu.2025.100853 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine Plus, 2025-08. Verfasst von Pengfei Guo und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine.
Abstract (Originalsprache)
Background
Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disorder of the brain characterized by an uncertain etiology and complex pathogenesis. Effective therapeutics remain urgently needed. Natural products (NPs) show significant potential in preventing/treating neurodegenerative diseases.
Methods
In this study, the network proximity method (NPM) identified the NP Lg0005 (p = 0.05, z = -3.11) with potential anti-AD activity. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses elucidated its anti-AD mechanism of action (MOA). Neuroprotective effects were validated using D-galactose (D-gal)-induced AD rat models and SH-SY5Y cells.
Results
KEGG analysis revealed Lg0005 primarily acts via AD, oxidative phosphorylation, apoptosis, and TNF signaling pathways, etc. GO analysis indicated it targets mitochondrial electron transport, mitochondrial components, and oxidoreductase activities, etc. Molecular docking and in vitro/in vivo experiments confirmed Lg0005 inhibited microglia/astrocyte activation, reducing TNF-α and IL-1β release. In addition, it alleviated oxidative damage by decreasing MDA and increasing catalase, ameliorated mitochondrial ultrastructural damage, and increased both Nissl body count and synaptic density in the hippocampal DG region, with efficacy comparable to β-nicotinamide mononucleotide (NMN) and donepezil. In summary, Lg0005 significantly improved cognitive function in AD models by reducing oxidative stress, suppressing neuroinflammation, and protecting mitochondrial and neuronal integrity.
Conclusions
Integrating NPM, network pharmacology, and experimental validation, this study identified Lg0005 as a novel anti-AD candidate, offering a new strategy for neurodegenerative disease therapeutics.
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
Zitieren
APA
Guo, P., Zhao, J., Zhang, B., Wang, C., Bai, Y., & Liu, A. (2025). Isorhapontigenin, a potential anti-AD natural product targeting multiple pathways, discovered via network proximity and gene enrichment analyses. Phytomedicine Plus, 5(3), 100853. https://doi.org/10.1016/j.phyplu.2025.100853
Vancouver
Guo P, Zhao J, Zhang B, Wang C, Bai Y, Liu A. Isorhapontigenin, a potential anti-AD natural product targeting multiple pathways, discovered via network proximity and gene enrichment analyses. Phytomedicine Plus. 2025;5(3):100853. doi:10.1016/j.phyplu.2025.100853
BibTeX
@article{Guo2025,
author = {Guo, Pengfei and Zhao, Jun and Zhang, Baoyue and Wang, Chao and Bai, Yiming and Liu, Ailin},
title = {Isorhapontigenin, a potential anti-AD natural product targeting multiple pathways, discovered via network proximity and gene enrichment analyses},
journal = {Phytomedicine Plus},
year = {2025},
volume = {5},
number = {3},
pages = {100853},
doi = {10.1016/j.phyplu.2025.100853}
}
EUVIMED